Skip to main content
. 2011 Jan 24;108(6):2605–2610. doi: 10.1073/pnas.1015788108

Fig. 4.

Fig. 4.

Point mutations in C-terminal domain regulate TREK1 response to GPCR activation. (A) Percentage of current inhibition by 5HT2cR activation for TREK1-WT, TREK1-Penta-A, TREK1-E306, TREK1-S300A, and TREK1-WT preincubated with calphostatin C. (B) Relative fluorescence decrease induced by 5HT2cR activation for EGFP-CtTREK1 WT, EGFP-CtTREK1-Penta-A, EGFP-CtTREK1-E306, EGFP-CtTREK1-S300A, and TREK1-WT preincubated with calphostatin C (overnight 5 μM). The asterisks indicate the significance (P < 0.05) of the difference between TREK1 mutants and TREK1-WT (or EGFP-CtTREK1 mutants and EGFP-CtTREK1). Student's t test: ***P < 0.001. The numbers of cells tested are indicated in parentheses.